Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 18/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18056634 | 0.87 | ROCK1 (0.77) | ROCK1ROCK2 | |
| SCHEMBL18056260 | 0.85 | ROCK1 (0.81) | ROCK1ROCK2 | |
| SCHEMBL18056547 | 0.84 | ROCK1 (0.73) | ROCK1ROCK2 | |
| SCHEMBL18056262 | 0.84 | ROCK2 (1.00) | ROCK1ROCK2 | |
| SCHEMBL20029972 | 0.81 | ROCK1 (0.68) | ROCK1ROCK2 | |
| SCHEMBL18056544 | 0.81 | ROCK1 (0.87) | ROCK1ROCK2 | |
| SCHEMBL18056485 | 0.81 | ROCK1 (0.80) | ROCK1ROCK2 | |
| SCHEMBL18056480 | 0.81 | ROCK1 (0.80) | ROCK1ROCK2 | |
| SCHEMBL18056402 | 0.81 | ROCK1 (1.00) | ROCK1ROCK2 | |
| SCHEMBL18056483 | 0.81 | ROCK1 (1.00) | ROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093978-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-04-05 | — | — | US | disclosed |
| WO-2016138335-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | LYCERA CORPORATION (US) | 2016-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093978-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | ROCK1, ROCK2, CIT | ROCK1 1/4885ROCK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.